Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc.
19900 MacArthur Boulevard
Suite 550
Irvine, CA 92612
United States
(949) 238-8090
https://eledon.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 20
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | CEO & Non Independent Director | 866.35k | N/D | 1972 |
| Dr. Steven N. Perrin Ph.D. | President, Chief Scientific Officer & Non Independent Director | 634.15k | N/D | 1966 |
| Mr. Paul Sean Little | Chief Financial Officer | 622.04k | N/D | 1965 |
| Mr. John Herberger | Vice President of Technical Operations | N/D | N/D | N/D |
| Mr. Bryan E. Smith J.D. | General Counsel, Corporate Secretary & Chief Compliance Officer | 377.14k | N/D | 1980 |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer | N/D | N/D | N/D |
| Dr. Eliezer Katz F.A.C.S., FACS, M.D. | Chief Medical Officer | N/D | N/D | N/D |
Descripción
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Eledon Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
